CN107802621A - The purposes of the anti-neuroinflamation of artemisinin B and treatment nerve degenerative diseases - Google Patents
The purposes of the anti-neuroinflamation of artemisinin B and treatment nerve degenerative diseases Download PDFInfo
- Publication number
- CN107802621A CN107802621A CN201711272956.7A CN201711272956A CN107802621A CN 107802621 A CN107802621 A CN 107802621A CN 201711272956 A CN201711272956 A CN 201711272956A CN 107802621 A CN107802621 A CN 107802621A
- Authority
- CN
- China
- Prior art keywords
- artemisinin
- application
- medicine
- degenerative diseases
- nerve degenerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of new application of traditional Chinese medicine ingredients artemisinin B, particularly application of the artemisinin B in the medicine for preparing anti-neuroinflamation, wherein described neuroinflamation is lipopolysaccharide-induced Deiter's cells inflammation, the present invention further provides application of the artemisinin B in the medicine for preparing treatment nerve degenerative diseases, wherein, described nerve degenerative diseases are characterized by learning memory disorder, wherein, described nerve degenerative diseases include Alzheimer disease, Parkinson, Heng Shi Dun Shi diseases, the present invention further provides artemisinin B to prepare improvement Spatial memory obstacle, improve the application in the medicine of learning and memory, wherein, Spatial memory obstacle is the learning memory disorder caused by the intracerebroventriculars of A β 25 35.
Description
Technical field
The present invention relates to a kind of new application of traditional Chinese medicine ingredients artemisinin B, particularly anti-neuritis is being prepared using artemisinin B
Application in the medicine of disease and treatment cognition dysfunction, and the compound is in Alzheimer disease, Parkinson's, Huntingdon
Application in the nerve degenerative diseases such as family name's disease.
Background technology
Nerve degenerative diseases (Neurodegenerative disease) are a kind of chronic, progressive nervous systems
Disease, pathological characters are largely collected as with the uncontrollable loss of neuron in brain and spinal cord and specific protein, with brain work(
It can decline, the particularly decline of cognitive function and motor function.It includes most common senile dementia, i.e. Alzheimer disease
(Alzheimer's Disease, AD), and the Parkinson's (Parkinson's characterized by static tremor
Disease, PD), the multiple sclerosis (Multiple Sclerosis, MS) characterized by movement defect, with progressive flesh
Powerless ALS (amyotrophic lateral sclerosis, ALS) being characterized etc..With global people
Mouth aging and the average life span extend, and drastically elevated chronic disease and healthy detraction level will choose as dominant world public health
War, nerve degenerative diseases have become the health burden of the mankind.By taking AD as an example, whole world patient populations are estimated by by present
4,400 ten thousand increase to the 13 of the year two thousand fifty, and 5,000,000, society and family will be given to cause great burden.
In the disease process of a variety of nerve degenerative diseases, neuroinflamation is considered as crucial pathogenesis.Nerve
Inflammation is using the activation of Deiter's cells as principal character.Inflammation can make intracerebral spongiocyte be activated repeatedly, cause repair machine
System imbalance or activation signal are persistently present, and are changed into the chronic inflammation for being relatively difficult to control damage common in the nervous system disease
Wound.Substantial amounts of neurotoxicity factor etc. can be discharged again simultaneously, increases the oxidative stress of neuron, so as to cause impaired brain area nerve
The retrogression pathological changes of member.For example, AD patient's intracerebral inflammatory factor can promote A β generation, the phosphorus of Protein tau by a variety of paths
Acidifying；Then A β aggregation can raise the expression of TNF-α, iNOS, IL-6mRNA by MARK signal paths again, and induce intracerebral
Different brain region CB2R mRNA expressions up-regulation.In addition, A β can stimulate Deiter's cells to activate, discharge substantial amounts of inflammation because
Son, such as TNF-α, TGF-β, IL-6 and IL-1, induce denaturation, the death of neuron of cynapse.PD neuroinflamations are led
To be interacted due to maincenter and the immunocyte of periphery, release proinflammatory cytokine (TNF-α, IL-1 β and IL-6) amplification is scorching
Disease signal, produce neurotoxin and directly act on dopamine neuron, it is dead [] to ultimately result in dopamine neuron.MS rats
Around brain tissue blood vessel and brain parenchym has obvious inflammatory cell infiltration；There is the intensive ring of a large amount of inflammatory cells around spinal cord blood vessel
Around in " oversleeve sample " change；Spinal cord myelin large area depigmentation, and myelin flaggy is loose.Positron emission computed tomography
Being shown in has the activation of microglia in the brain of ALS patient.Inflammatory process is not only developed to middle and advanced stage appearance
Secondary response, and just participate in its pathologic process in the stage that originates.Therefore, the generation of neuroinflamation is suppressed with developing for maincenter
The preventing and treating of the nervous system disease is significant.
Artemisinin B (Arteannuin B, CAS No.50906-56-4) is from Chinese medicine sweet wormwood (Arterisia annua
L. the isolated Sesquiterpene lactones compound of extraction in).Its chemical structural formula is as follows：
The preparation method and its new application of the artemisinin B of Chinese patent 201110388382.6 disclose the preparation of artemisinin B
Method and its for preparing immunosuppressive medicine, artemisinin B has significant immunosuppressive activity, can prepare prevention and control
Treat autoimmune disease, diseases associated with inflammation medicine and clinically apply.Modern age pharmaceutical research shows that it has certain journey
Antimalarial, antibacterium, anti-tumor metastasis, the antimycotic and antipyretic activity of degree.But so far there is not yet artemisinin B is used for
Treatment nerve degenerative diseases especially treat the report of senile dementia.
The content of the invention：
It is an object of the invention to provide application of the artemisinin B in anti-neuroinflamation.
Specifically include：
Application of the artemisinin B in the medicine for preparing anti-neuroinflamation.
Wherein described neuroinflamation is lipopolysaccharide-induced Deiter's cells inflammation.
The present invention further provides application of the artemisinin B in the medicine for preparing treatment nerve degenerative diseases.
Wherein, described nerve degenerative diseases are characterized by learning memory disorder.
Wherein, described nerve degenerative diseases include Alzheimer disease, Parkinson, Heng Shi Dun Shi diseases.
The present invention further provides artemisinin B to prepare improvement Spatial memory obstacle, improves the medicine of learning and memory
In application.
Wherein, Spatial memory obstacle is the learning memory disorder caused by A β 25-35 intracerebroventriculars.
The present invention pharmaceutical composition that also offer is prepared into by the use of artemisinin B as active constituents of medicine, medicine of the invention
Composition, including artemisinin B, said composition as needed can also add pharmaceutically acceptable carrier.
The composition of the present invention, is the pharmaceutical dosage forms of unit dose, and the unit dosage form refers to the list of preparation
Position, such as every of tablet, every capsule of capsule, every bottle of oral liquid, every bag of granule etc..
The composition active principle therein of the present invention, shared percentage by weight can be 0.1- in the formulation for it
99.9%, remaining is pharmaceutically acceptable carrier.
The composition of the present invention, by the way that above-mentioned active principle and pharmaceutically acceptable carrier to be mixed with to obtain.
The composition of the present invention, its pharmaceutical dosage forms can be any pharmaceutically useful formulation, and these formulations include：Piece
Agent, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, mouth containing agent, particle
Agent, electuary, pill, powder, paste, sublimed preparation, supensoid agent, pulvis, solution, injection, suppository, ointment, emplastrum, frost
Agent, spray, drops, patch.The preparation of the present invention, preferably peroral dosage form, such as：Capsule, tablet, oral liquid, particle
Agent, pill, powder, sublimed preparation, paste etc..
The composition of the present invention, its preparation being administered orally containing conventional excipient, such as adhesive, filler,
Diluent, tablet agent, lubricant, disintegrant, colouring agent, flavor enhancement and wetting agent, tablet can be coated if necessary.
Applicable filler includes cellulose, mannitol, lactose and other similar fillers.Suitable disintegrant bag
Include starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycollate.Suitable lubricant includes, such as firmly
Fatty acid magnesium.Suitable pharmaceutically acceptable wetting agent includes lauryl sodium sulfate.
Solid oral composition can be prepared by conventional methods such as mixing, filling, tablettings.Work can be made by carrying out mixing repeatedly
Property material be distributed in entirely using a large amount of fillers those compositions in.
The form of oral liquid for example can be water-based or oily suspensions, solution, emulsion, syrup or elixir,
Or can be a kind of dry products that water or other suitable carriers can be used to compound before use.This liquid preparation can contain
Conventional additive, such as suspending agent, such as sorbierite, syrup, methylcellulose, gelatin, hydroxyethyl cellulose, carboxymethyl are fine
Dimension element, aluminium stearate gel or hydrogenated edible fats, emulsifying agent, such as lecithin, anhydro sorbitol monooleate or Arab
Glue；Non-aqueous carrier (they can include edible oil), such as the oily ester of the ester of apricot kernel oil, fractionated coconut oil, such as glycerine,
Propane diols or ethanol；Preservative, such as para hydroxybenzene methyl esters or propylparaben or sorbic acid, and if desired,
Contain conventional flavouring agent or colouring agent.
For injection, the fluid unit dosage form of preparation contains the active material and sterile carrier of the present invention.According to carrier
And concentration, this compound can be suspended or be dissolved.The preparation of solution is dissolved in a kind of load typically by by active material
In body, sterilization is filtered before a kind of suitable bottle or ampoule is loaded into, is then sealed.For example a kind of local anaesthesia of auxiliary material
Agent, preservative and buffer can also be dissolved in this carrier., can be after bottle be loaded by this in order to improve its stability
Kind composition frost, and under vacuo remove water.
The composition of the present invention, suitable pharmaceutically acceptable carrier, institute are optionally added when being prepared into medicament
Pharmaceutically acceptable carrier is stated to be selected from：Mannitol, sorbierite, sodium pyrosulfite, sodium hydrogensulfite, sodium thiosulfate, hydrochloric acid half
Cystine, TGA, methionine, injection Vitamin B_6 DTA disodiums, EDTA calcium sodium, the carbonate of monovalence alkali metal, acetate,
Phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, xylitol, malt
Sugar, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and its spread out
Biology, alginates, gelatin, polyvinylpyrrolidone, glycerine, POLYSORBATE 80, agar, calcium carbonate, calcium bicarbonate, surfactant,
Polyethylene glycol, cyclodextrin, beta-schardinger dextrin, phospholipid material, kaolin, talcum powder, calcium stearate, magnesium stearate etc..
The composition of the present invention determines usage and dosage according to the situation of patient when in use, can often taken three times per day, each 1-
20 doses, such as：1-20 bags or grain or piece.
Brief description of the drawings：
Fig. 1 artemisinin Bs are to BV-2 cytotoxicities
The influence for the BV-2 cells secretion NO that Fig. 2 artemisinin Bs are induced LPS
Fig. 3 artemisinin Bs are to IL-1 β, IL-6, TNF-α, MyD88, the horizontal influence changed of NF- κ 1 B genes
Influence of Fig. 4 artemisinin Bs to A β intracerebroventricular model mice water maze orientation navigation experiment Middle latencies
Influence of Fig. 5 artemisinin Bs to total distance of swimming in A β intracerebroventricular model mice water maze orientation navigation experiments
Fig. 6 artemisinin Bs are to wearing the influence of platform number in A β intracerebroventricular model mice water maze explorative experiments
Influence of Fig. 7 artemisinin Bs to the target quadrant distance of swimming in A β intracerebroventricular model mice water maze explorative experiments
Influence of Fig. 8 artemisinin Bs to A β intracerebroventricular model mice step-through test Middle latencies
Influence of Fig. 9 artemisinin Bs to errors number in A β intracerebroventricular model mice step-through tests
Specific embodiment：
The present invention is further illustrated by the following examples.
Experimental example 1：The Effect study of the BV-2 cellular neural inflammation of the anti-LPS inductions of artemisinin B
Experimental method：
(1) external BV2 cells：BV2 cells used are purchased from Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences's cellular resources
The heart, condition of culture are that DMEM/F12 nutrient solutions (add 10% import hyclone, 100X nonessential amino acid, penicillin
100UmL-1 and streptomysin 100UmL-1), 37 DEG C, cultivate under the conditions of 5%CO2.
(2) srb assay detection cytotoxicity：
The BV2 cells in growth period of taking the logarithm carry out bed board, will count after cell dissociation, are connect by 2*10^5/ml density
Kind is in 96 orifice plates, per the μ L of hole 100.The effective component of chinese medicine of various concentrations is added after 4 hour cells are adherent, continues culture 24
Hour.Culture plate is taken out, 50ul TCA solution is gently added and fixes, 1h is placed under the conditions of going to 4 DEG C after standing 10min.Outwell
Fixer, deionization are washed 5 times, and room temperature is dried.100ul SRB are added per hole to dye, and 5 are washed with 1% acetic acid after standing 10min
Time, room temperature is dried.The concussion dissolving of 150ul Tris aqueous slkalis is added per hole, its OD value is detected under wavelength 490nm, according to suction
Shading value calculates cell survival rate.
(3) Griess reagents method detection NO contents：
The BV2 cells in growth period of taking the logarithm carry out bed board, will count after cell dissociation, are connect by 2*10^5/ml density
Kind is in 96 orifice plates, per the μ L of hole 100.After cell attachment, it is divided into Normal group, LPS model groups, LPS and drug-treated group,
Corresponding solution is added, per hole totally 200 μ L.Supernatant is taken to be detected after culture 24h.Sample and standard items are separately added into 96 orifice plates
50 μ L, Griess reagent As 50 μ L, 37 DEG C of placement 10min are added, add the μ L of Griess reagents B 50,37 DEG C of placements
10min, OD values are determined at ELIASA 540nm.Using NaNO2 as standard items, standard curve is drawn.
(4) ELISA detects cell factor：
The BV2 cells in growth period of taking the logarithm carry out bed board, will count after cell dissociation, are connect by 2*10^5/ml density
Kind is in 12 orifice plates, per hole 1ml.After cell attachment, it is divided into Normal group, LPS model groups, LPS and drug-treated group,
Add corresponding solution.Cell culture supernatant is taken after culture 24h, 4 DEG C, 5000 r/min centrifugation 10min, is collected on nutrient solution
Clearly.Concrete operations are carried out according to ELISA kit specification.
(5) real-time fluorescence quantitative PCR detection mRNA level in-site change：
The BV2 cells in growth period of taking the logarithm carry out bed board, will count after cell dissociation, are connect by 2*10^5/ml density
Kind is in 6 orifice plates, per hole 2ml.Suck old nutrient solution after overnight incubation, medicine group adds drug solution 1ml, blank control group and
Model group adds nutrient solution 1ml, and model group and each hole of medicine group add LPS solution 1ml after preincubate 2h, and blank control group adds training
Nutrient solution 1ml.Continue to add Trizolz progress cell lysis after cultivating 6h, carry out reverse transcription after extracting total serum IgE, then carry out q-PCR
Carry out DNA cloning, the horizontal change of detection IL-1 β, IL-6, TNF-α, MyD88, NF- κ 1 B genes.
Experimental result：See Fig. 1-3
Experimental example 2：The influence that artemisinin B intends A β intracerebroventriculars AD model mice learning and memories is studied
Experimental method：
(1) Naoliqing capsule is injected：10ul A β (ug/ul) are injected in rat brain with solid locating method, are established anxious
Property intracerebral inflammatory model.10% chloraldurate 350mg/kg intraperitoneal injection of anesthesia of rat, it is three-dimensional fixed that rat is then placed in brain
On the instrument of position, fixing head.The hair on the rat crown is shaved off, conventional alcohol sterilization, Jian scalps is cut, exposure parietal bone, is stood with reference to rat brain
Body positions collection of illustrative plates, and two apertures are bored on parietal bone.The specific of hippocampus is positioned as：Using bregma as zero point, center line both sides are by backward
It is preceding away from bregma point 4mm, both sides are away from center line 2.8mm, Subdural space 3.1mm.The 4mm i.e. after bregma, center line open 2.8mm by both sides, are
Point of puncture.Bored with dental drill and open skull, stab out dura mater with micro syringe, vertical inserting needle reaches Subdural space 3.1mm, as hippocampus CA1
Area.Slowly injection LPS, each 2.5ul of bilateral hippocampus, every side are extra large into hippocampus for Acetylpuerarin group and group micro syringe
The injection time of horse, let the acupuncture needle remain at a certain point 5min was to ensure the abundant disperse of solution, double injection interval 10 minutes more than 20 minutes.Slowly extract
Micro syringe, closing drilling, spills a little penicillin powder, then skin suture in skull surface, chelated iodine sterilization.
(2) animal behavioral study：Water maze is made up of the platform of a stainless steel round pool and a moveable position, a diameter of
100cm, depth of water 30cm.The first injected clear water in pond, then adding a little prepared Chinese ink makes water become opaque, and water temperature control exists
(22±2)℃.Pond is divided into 4 identical quadrants, and mark of different shapes is posted above the pool wall of each quadrant as ginseng
According to thing, platform is located at the centre of some quadrant, and the water surface is higher by platform 2cm.Test totally 6 days, is determined respectively:(1) orientation navigation is real
Test:Test the 1st~4 day, per two periods of the natural gift morning and afternoon, each period instructs 2 times, respectively by mouse from two as
Limit and tested into water, record its escape latency (from water is entered to the time for finding security platform), be defined to 70s during test.It is if small
Mouse not yet finds platform in 70s, then takes on platform mouse and it is stopped 30s above；If found in mouse 70s flat
Platform, also it is allowed to stop 30s on platform.Pond overhead is connected by video camera with monitor and computer, is examined using water maze
Software systems are surveyed from motion tracking mouse swimming track.(2) space search is tested:Test the 5th day, remove platform, mouse is in Yuanping City
The offside quadrant of platform quadrant enters water, and the swimming distance of quadrant accounts for the percentage (%) of total distance, time where recording its original platform
Percentage (%).(3) visualisation platforms are tested:Test the 6th day, pond inner platform is higher by water surface 2cm, put in platform offside quadrant
Enter mouse, its escape latency is recorded in the case of mouse is visual, influence of the mouse eyesight to searching platform is excluded with this.
(3) morphological observation：Histotomy is made, immunofluorescence is carried out to section and SABC detects, observes colloid
Hyperplasia and the loss situation of neuron；And Gorky's dyeing is carried out to hippocampal tissue, observation synapse form changes
Become.
(4) immunology detection：Injection LPS gives intraperitoneal injection 1% anaesthetized with pentobarbital after 12 hours, thoroughly anesthesia
After take brain, put in liquid nitrogen container and preserve.Inflammatory factor IL-6 and TNF-a are detected using elisa technique, using Diagnosis of Sghistosomiasis
Mark technology for detection MyD88, NF- kB protein is horizontal.Specific steps are same as above.
Experimental result：See Fig. 4-9.
Claims (10)
1. application of the artemisinin B in the medicine for preparing anti-neuroinflamation.
2. application according to claim 1, wherein the neuroinflamation is lipopolysaccharide-induced Deiter's cells inflammation.
3. application of the artemisinin B in the medicine for preparing treatment nerve degenerative diseases.
4. application according to claim 3, wherein, described nerve degenerative diseases are characterized by learning memory disorder
's.
5. application according to claim 3, wherein, described nerve degenerative diseases include Alzheimer disease, pa gold
It is gloomy, Heng Shi Dun Shi diseases.
6. artemisinin B is preparing improvement Spatial memory obstacle, the application in the medicine of learning and memory is improved.
7. application according to claim 6, wherein, Spatial memory obstacle is caused by A β 25-35 intracerebroventriculars
Practise memory disorders.
8. according to the application described in claim 1-7 any one, wherein the medicine be by the use of artemisinin B as pharmaceutical activity into
Divide the pharmaceutical composition being prepared into.
9. according to the application described in claim 1-7 any one, wherein the medicine includes artemisinin B and pharmaceutically acceptable
Carrier.
10. according to the application described in claim 1-7 any one, wherein the medicine is any pharmaceutically useful formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711272956.7A CN107802621A (en) | 2017-12-06 | 2017-12-06 | The purposes of the anti-neuroinflamation of artemisinin B and treatment nerve degenerative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711272956.7A CN107802621A (en) | 2017-12-06 | 2017-12-06 | The purposes of the anti-neuroinflamation of artemisinin B and treatment nerve degenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107802621A true CN107802621A (en) | 2018-03-16 |
Family
ID=61579370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711272956.7A Pending CN107802621A (en) | 2017-12-06 | 2017-12-06 | The purposes of the anti-neuroinflamation of artemisinin B and treatment nerve degenerative diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107802621A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113662977A (en) * | 2020-05-15 | 2021-11-19 | 澳门大学 | Application of artemisia annua extract in preparation of preparation for treating or preventing AD |
| CN114470038A (en) * | 2022-03-28 | 2022-05-13 | 北京诺迪博尔医药科技有限公司 | Composition for treating Alzheimer disease-senile cognitive disorder |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008143876A2 (en) * | 2007-05-14 | 2008-11-27 | The Trustees Of Columia University In The City Of New York | Agents and assays for modulating neurodegeneration |
| CN102408431A (en) * | 2011-11-29 | 2012-04-11 | 中国中医科学院中药研究所 | Preparation method and new application of artemisinin B |
| CN103948585A (en) * | 2014-04-17 | 2014-07-30 | 中山大学中山眼科中心 | Application of artemisinin in preparing medicament for preventing and treating neurological diseases |
| CN105147666A (en) * | 2015-09-09 | 2015-12-16 | 云南大学 | Compound for treating and relieving neurodegenerative disease |
-
2017
- 2017-12-06 CN CN201711272956.7A patent/CN107802621A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008143876A2 (en) * | 2007-05-14 | 2008-11-27 | The Trustees Of Columia University In The City Of New York | Agents and assays for modulating neurodegeneration |
| CN102408431A (en) * | 2011-11-29 | 2012-04-11 | 中国中医科学院中药研究所 | Preparation method and new application of artemisinin B |
| CN103948585A (en) * | 2014-04-17 | 2014-07-30 | 中山大学中山眼科中心 | Application of artemisinin in preparing medicament for preventing and treating neurological diseases |
| CN105147666A (en) * | 2015-09-09 | 2015-12-16 | 云南大学 | Compound for treating and relieving neurodegenerative disease |
Non-Patent Citations (4)
| Title |
|---|
| BENJAMIN G HOFFSTROM 等: "Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins", 《NATURE CHEMICAL BIOLOGY》 * |
| 王晓良主编: "《应用分子药理学》", 30 September 2015, 中国协和医科大学出版社 * |
| 覃万翔 等: "双氢青蒿素抑制LPS 诱导的小胶质细胞炎症反应", 《第三军医大学学报》 * |
| 陈湛愔 等主编: "《老年痴呆症》", 31 May 2003, 广州出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113662977A (en) * | 2020-05-15 | 2021-11-19 | 澳门大学 | Application of artemisia annua extract in preparation of preparation for treating or preventing AD |
| CN114470038A (en) * | 2022-03-28 | 2022-05-13 | 北京诺迪博尔医药科技有限公司 | Composition for treating Alzheimer disease-senile cognitive disorder |
| CN114470038B (en) * | 2022-03-28 | 2023-10-24 | 北京诺迪博尔医药科技有限公司 | Composition for treating Alzheimer's disease-senile cognitive dysfunction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210008139A1 (en) | Cannabis compositions and methods | |
| Ming-Gang | Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years’ experience | |
| CN104274518B (en) | A kind of Chinese medicine composition and preparation | |
| CN104274520B (en) | A kind of Chinese medicine composition and its preparation | |
| CN1528315A (en) | Method for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists | |
| JP2012529487A (en) | Compositions and methods for prevention and treatment of brain diseases and conditions | |
| CN107802621A (en) | The purposes of the anti-neuroinflamation of artemisinin B and treatment nerve degenerative diseases | |
| CN109432096A (en) | Hydrochloric acid goes application of the methylene N-1 in preparation prevention or treatment alcoholic liver disease and non-alcoholic fatty liver disease drug | |
| CN102526065B (en) | Compound injection preparation for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| JP7287937B2 (en) | Composition used for regulation of intestinal permeability and/or treatment and/or prevention of intestinal wall leakage-related diseases | |
| CN101904838A (en) | Application of ligustilide in preparing composition for preventing and treating senile dementia | |
| CN1565441A (en) | Use of levobutylphthalide in prevention and cure of dementia | |
| CN111437323A (en) | Application of vine tea extract in medicine for preventing and treating Alzheimer disease | |
| CN108697663A (en) | The method that caspase inhibitors are used in liver disease | |
| CN109771411A (en) | Dihydroquercetin is used to prepare the purposes in the drug for the treatment of fatty liver | |
| CN101627984A (en) | Application of 2-(alpha- hydroxyl amyl) potassium benzoate in preventing and/or treating senile dementia | |
| CN1486691A (en) | Bolengsu compound and its prepn, medicine composition and use | |
| CN106344609A (en) | Application of ozonized oil in preventing and controlling nervous system diseases | |
| CN105037354A (en) | Application of pyrazine isoquinoline derivatives in preparing drugs for treating schistosomes | |
| JP7090731B2 (en) | New pharmaceutical uses of persimmon leaf extract and its preparations | |
| CN102241628A (en) | (2E)-3-phenyl-N-[2,2,2-trichlorine-1-[[(8-quinolyl amino) thiomethyl]amino]ethyl]-2-acrylamide and medicinal uses thereof | |
| Rwang et al. | Evaluation and phytochemical analysis of Prosopis africana and Erythrina senegalensis used against immature stages of Schistosoma haematobium | |
| CN104096089A (en) | Traditional Chinese medicine composition for treating ischemia apoplexy, and capsules and preparation method thereof | |
| CN114469967B (en) | Application of atractyloside A and derivatives thereof in preparation of anxiolytic and antidepressant drugs | |
| WO2013111013A2 (en) | Methods for treating alzheimer's disease by administering certain synthetic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180316 |